Key Takeaway: Nurix is advancing its portfolio focused on targeted protein degradation, particularly concerning BTK, to address resistance mutations in cancer therapies. The company aims to translate scientific insights into effective treatments for cancer and autoimmune diseases. Their approach highlights the potential of novel therapies in overcoming challenges faced in current treatments.
Price reaction · baseline $8.48 (2023-09-25 close) · hit pre-market · 2 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on targeted protein degradation as a novel therapeutic approach.
Advancements in overcoming resistance mutations in cancer treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is targeted protein degradation?
Targeted protein degradation is a therapeutic approach that aims to eliminate specific proteins involved in disease processes.
How does Nurix address resistance mutations?
Nurix focuses on targeted protein degradation to overcome clinically-relevant resistance mutations in cancer.
What diseases does Nurix aim to treat?
Nurix is dedicated to developing therapies for cancer and autoimmune diseases.